Chemical stability and physical compatibility of meropenem in admixtures for continuous and extended intravenous infusions.

Introduction: Prolonged intravenous infusion of beta-lactams increase the clinical cure rate compared to conventional administration in critical or septic patients. This study aimed to determine chemical stability and physical compatibility of meropenem at conditions used in clinical practice to evaluate the stability of the preparation during its administration and the possibility of anticipated preparation.

Methods: Admixtures in study were: (i) meropenem 6g in 0.

Clinical utility of serum concentrations of adalimumab as predictor of treatment adherence.

Objective: to evaluate the usefulness of serum concentrations (Sc) of adalimumab (ADA) as a predictor of medication adherence using the medication possession ratio (MPR) and Morisky Green test (MGT) in patients with chronic inflammatory diseases.

Material And Method: Design a prospective descriptive cohort study.

Inclusion Criteria: adult patients diagnosed with inflammatory arthropathy (IA) or inflammatory bowel disease (IBD) treated with ADA.

Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study.

Objective: CT-P13 is a biosimilar with comparable pharmacokinetics, efficacy and safety to its reference product (RP), infliximab. Studies have shown that switching from RP to CT-P13 does not reduce the effectiveness or safety of treatment.

Methods: In this retrospective real-world study, patients with inflammatory diseases treated with RP were switched to CT-P13 (n = 7) or continued on RP (n = 6).

Chemotherapy dose intensity reductions due to adverse drug reactions in an oncology outpatient setting.

Objective: the aim of this study was to establish the incidence of adverse drug reactions (ADRs) that prevent administration of planned dose intensity antineoplastic chemotherapy in clinical practice.

Methods: a retrospective cohort study was made of adult oncology patients who received intravenous chemotherapy in an outpatient ward during 2005. Dose delays, dose reductions, dose omissions, or treatment discontinuations with respect to the planned chemotherapy regimen were obtained, and causes were evaluated to identify ADRs.